Tamoxifen can reverse multidrug resistance of colorectal carcinoma in vivo

Figure 1 mdr1 mRNA expression of tumors from three patients. Lane 1: DNA marker, lane 2: positive control, lane 3: negative control, lane 4: patient III, lane 5: patient I, lane 6: patient II.

Figure 2 The volumes and weights of mdr1-positive and ER-positive tumors, 1: the tumor volumes in the beginning of treatment, 2: the tumor volumes at the end of the first course, 3: the tumor volumes at the end of the second course, 4: the tumor weights at the end of the second course.

Figure 3 The volumes and weights of mdr1-positive and ER-negative tumors, 1: the tumor volumes in the beginning of treatment, 2: the tumor volumes by the end of the first course, 3: the tumor volumes at the end of the second course, 4: the tumor weights at the end of the second course.

Figure 4 The volumes and weights of mdr1 negative tumors, 1: the tumor volumes in the beginning of treatment, 2: the tumor volumes at the end of the first course, 3: the tumor volumes at the end of the second course, 4: the tumor weights at the end of the second course.

Figure 5 mdr1 mRNA levels of mdr1-positive tumors after treatment.